Friday, October 07, 2022 8:09:36 PM
skitahoe,
I agree with you that combos will be explored but I also believe NWBO has some of their own ideas up their sleeve already. The danger for big pharma has always been from underestimating what the DCVax platform potential really is and how well prepared NWBO is set to move that potential forward. Remember, what is most important to NWBO is what is least talked about. Just because there aren’t a great many ongoing trials with L or Direct doesn’t mean that they haven’t figured out some very important things from the data they do have and from what they have come to understand from what others have shared with them from their own developments with regard to immunotherapy. When is the last time we talked about INMune Bio? Sooooooo much info to get out and the ability to understand how it all fits together is often limited by focus. This is a disruptive technology and the attempt to harness the implications is going to be very difficult unless a plan has been put in place and I think it has been. Amazing!; ). Best wishes.
I agree with you that combos will be explored but I also believe NWBO has some of their own ideas up their sleeve already. The danger for big pharma has always been from underestimating what the DCVax platform potential really is and how well prepared NWBO is set to move that potential forward. Remember, what is most important to NWBO is what is least talked about. Just because there aren’t a great many ongoing trials with L or Direct doesn’t mean that they haven’t figured out some very important things from the data they do have and from what they have come to understand from what others have shared with them from their own developments with regard to immunotherapy. When is the last time we talked about INMune Bio? Sooooooo much info to get out and the ability to understand how it all fits together is often limited by focus. This is a disruptive technology and the attempt to harness the implications is going to be very difficult unless a plan has been put in place and I think it has been. Amazing!; ). Best wishes.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
